Cargando…
A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV‐2 (COVID‐19) DHODH (dihydroorotate dehydrogenase) inhibitor
A therapeutic agent that targets both viral replication and the hyper‐reactive immune response would offer a highly desirable treatment for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; COVID‐19) management. Emvododstat (PTC299) was found to be a potent inhibitor of immunomodulatory a...
Autores principales: | Morton, Terri L., Laskin, Oscar L., Kaushik, Diksha, Lee, Lucy, Ma, Jiyuan, Kristensen, Allan, O'Keefe, Kylie, Golden, Lee, Klein, Matthew, Kong, Ronald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026081/ https://www.ncbi.nlm.nih.gov/pubmed/36938928 http://dx.doi.org/10.1002/prp2.1076 |
Ejemplares similares
-
A clinical pharmacokinetic drug-drug interaction study between dextromethorphan and emvododstat, a potent anti-SARS-CoV-2 dihydroorotate dehydrogenase inhibitor
por: Morton, Terri L., et al.
Publicado: (2023) -
Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia
por: Branstrom, Arthur, et al.
Publicado: (2022) -
Babesia bovis Dihydroorotate Dehydrogenase
(BboDHODH) is a Novel Molecular Target of Drug for Bovine Babesiosis
por: KAMYINGKIRD, Ketsarin, et al.
Publicado: (2013) -
Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology
por: Ladds, Marcus J. G.W., et al.
Publicado: (2021) -
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors “leflunomide” and “teriflunomide” in Covid-19: A narrative review
por: Kaur, Hardeep, et al.
Publicado: (2021)